News

VIDEO: ASCO 2014 roundtable on breast cancer research


 

AT THE ASCO ANNUAL MEETING 2014

CHICAGO – The Oncology Report associate editors Dr. William J. Gradishar and Dr. Hope S. Rugo discuss breast cancer research highlights presented at the 2014 annual meeting of the American Association of Clinical Oncology.

Studies discussed include the combined analysis of the SOFT and TEXT trials, looking at ovarian suppression in combination with either an aromatase inhibitor or tamoxifen; ALTTO, looking at the impact of a dual blockade against HER2, and the implications on the use of pCR in research and drug approval; ECOG 5103 adjuvant bevacizumab trial; and POEMS, looking at the possibility of preserving fertility during chemotherapy with the addition of goserelin.

Dr. William J. Gradishar is the Betsy Bramsen Professor of Breast Oncology at the Northwestern University, Chicago. Dr. Hope S. Rugo is a professor of medicine, University of California, San Francisco, and director, breast oncology and clinical trials education, UCSF Helen Diller Family Comprehensive Cancer Center.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

ASCO guidelines address targeted treatments of HER2-positive breast cancer
Breast Cancer ICYMI
Obesity increased breast cancer mortality only in premenopausal women
Breast Cancer ICYMI
Breast cancer fear contributes to prophylactic mastectomy rate
Breast Cancer ICYMI
Taking the data and findings into the real-world setting
Breast Cancer ICYMI
ASCO: Extend adjuvant endocrine therapy to 10 years
Breast Cancer ICYMI
ASCO 2014: Dr. Hope S. Rugo gives her top picks in breast cancer research
Breast Cancer ICYMI
VIDEO: Goserelin helps dodge ovarian failure in HR-negative breast cancer
Breast Cancer ICYMI
VIDEO: Less frequent zoledronic acid is safe, retains efficacy
Breast Cancer ICYMI
Goserelin improves fertility in HR-negative breast cancer
Breast Cancer ICYMI
VIDEO: New option arises for young women with hormone-sensitive breast cancer
Breast Cancer ICYMI